Biocon To Buttress India Market Glargine Supply From Malaysia Site
Executive Summary
Biocon expects to meet Indian requirements for its insulin glargine with supplies from both home and abroad. It plans to import the product from its Malaysian site and will need to do Phase IV studies in Indian patients, but underscores that no price increase is likely for the imported version to ensure affordable access.
You may also be interested in...
Biocon Staying Firm On Insulins Path, Including Glargine
Biocon has reported strong second-quarter earnings and underscored its interest in the insulins space, including insulin glargine, at least for now. Merck & Co recently called off plans to commercialize its Lantus version.
Biocon Staying Firm On Insulins Path, Including Glargine
Biocon has reported strong second-quarter earnings and underscored its interest in the insulins space, including insulin glargine, at least for now. Merck & Co recently called off plans to commercialize its Lantus version.
Keeping Track: Mylan Wins First US FDA Approval For Neulasta Biosimilar, But Lands A CRL For Insulin Glargine; Genentech Nabs Broad Full Approval For Venclexta, PV Indication For Rituxan
The latest drug development news and highlights from our US FDA Performance Tracker.